View our poster on Patient Characteristics And Management Of Juvenile Idiopathic Arthritis (JIA) In a Large, Representative Real-World Cohort. Click to view more!
BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]
Thu. Nov. 19, 2020 1:00 PM – 2:00 PM Register From accelerating clinical trials and gaining regulatory approval to expanding access and understanding market needs, this webinar will cover the basics of what makes real-world data regulatory and research grade and how it can transform your R&D and market access programs for autoimmune and other[…]
View our poster on Comparison of Symptoms, Treatments, and Healthcare Resource Utilization in Patients with Multiple Sclerosis by Sex in a Real-World Cohort in the United States. Click to view more!
August 13, 2020- Aetion In a recent interview, Kathryn Starzyk, epidemiologist and Head of Real-World Evidence (RWE) at OM1, shared what makes OM1’s data unique, and how she and her team partner with biopharma and health systems to generate RWE that helps researchers better understand patient journeys in disease areas including rheumatology and immunology. Read on[…]
